Haya Therapeutics
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $65M
Overview
Developing lncRNA-targeted therapies for cardiac fibrosis and related diseases.
CardiovascularFibrosis
Technology Platform
Proprietary platform for discovering and targeting disease-driving long non-coding RNAs (lncRNAs) with oligonucleotide therapeutics.
Funding History
1Total raised:$65M
Venture$65M
Opportunities
Potential to address large, untreated markets like cardiac fibrosis with a first-in-class mechanism.
Risk Factors
Unproven clinical validation for lncRNA targeting and challenges in tissue-specific delivery of oligonucleotides.
Competitive Landscape
Operates in the emerging lncRNA therapeutics field with few direct competitors but adjacent competition from broader anti-fibrotic and RNA companies.